Home ›
Kidney Cancer Trials ›
NCT07072234
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Trial Details
NCT ID NCT07072234
Phase PHASE1
Sponsor M.D. Anderson Cancer Center
Status RECRUITING
Cancer Type Kidney Cancer
Interventions Lymphodepleting chemotherapy Dexamethasone Fludarabine Cyclophosphamate TGFBR-2 KO CD70 CAR NK
Locations (sample) Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
Eligibility Criteria Participants must have histologically confirmed ccRCC that is metastatic or unresectable and for which standard curative or palliative measures do … Confirmation of CD70 expression ≥ 10% by immunohistochemistry staining of the participants primary renal tumor or a metastatic lesion biopsy specim… Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diamet…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →